Logo

American Heart Association

  106
  0


Final ID: MDP578

Impact of Neutrophil on Ischemic Risk in Acute Coronary Syndrome Patients Across Different Low Density Lipoprotein Cholesterol Levels

Abstract Body (Do not enter title and authors here): Background: Inflammation is a significant residual risk factor for coronary artery disease. While intensive lipid-lowering therapy has reduced the prevalence of plaque rupture, plaque erosion in acute coronary syndrome (ACS) patients is increasing, with neutrophils playing a crucial role. It remains unclear whether varying low-density lipoprotein cholesterol (LDL-C) levels modify the relationship between neutrophil count and ischemic risk in ACS patients.

Aim: To investigate the relationship between neutrophil counts and ischemic risk in ACS patients undergoing percutaneous coronary intervention (PCI) across different LDL-C levels.

Methods: This large cohort study enrolled consecutive 10724 patients undergoing PCI at Fuwai Hospital (Peking Union Medical College) throughout the year of 2013. Patients were divided into subgroups according to baseline LDL-C levels, with cut-off points at 1.8mmol/L or 1.4mmol/L. The primary endpoint was major adverse cardiovascular event (MACE), and the secondary endpoint was revascularization.

Results: Finally, 5717 ACS patients with PCI were included. The mean age was 58.43 ± 10.35 years, with 4399 (76.9%) being male. During the 5-year follow-up period, 1058 (18.5%) MACEs and 821 (14.4%) revascularizations were recorded. Restricted cubic spline analysis revealed a positive correlation between neutrophil and MACE and revascularizations only in patients with lower LDL-C levels (LDL-C <1.8 and LDL-C <1.4 mmol/L), but not in those with higher LDL-C levels (LDL-C ≥1.8 and LDL-C ≥1.4 mmol/L) (Figure 1). Multivariate Cox regression analysis showed that in the LDL-C <1.8 mmol/L group, each unit increase in neutrophil count was associated with a 1.129 times higher risk of MACE (HR 1.129; 95% CI 1.046-1.219) and a 1.130 times higher risk of revascularizations (HR 1.130; 95% CI 1.031-1.238). Similar findings were observed in the LDL-C <1.4 mmol/L group, where higher neutrophil was independent risk factors for MACE (HR 1.222; 95% CI 1.063-1.404) and revascularizations (HR 1.274; 95% CI 1.078-1.506). However, in patients with higher LDL-C levels (LDL-C ≥1.8 and LDL-C ≥1.4 mmol/L), neutrophil counts were not associated with outcomes (Table 1).

Conclusions:High neutrophil counts are a significant risk factor for ischemic events in ACS patients with low LDL-C levels, highlighting the potential benefits of targeting neutrophils-related inflammatory pathway in the management of ACS patients with well-controlled LDL-C levels.
  • Yan, Kailun  ( Fuwai Hospical, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Li, Jiawen  ( Fuwai Hospical, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Zhang, Kexin  ( Fuwai Hospical, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Liu, Menglu  ( Fuwai Hospical, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Yuan, Jinqing  ( Fuwai Hospical, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Zhao, Xueyan  ( Fuwai Hospical, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China )
  • Author Disclosures:
    Kailun Yan: DO NOT have relevant financial relationships | Jiawen Li: DO NOT have relevant financial relationships | Kexin Zhang: DO NOT have relevant financial relationships | Menglu Liu: DO NOT have relevant financial relationships | Jinqing Yuan: No Answer | Xueyan Zhao: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Biomarkers in ACS

Saturday, 11/16/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
A Novel CRISPR based Epigenetic Silencer Potently, Durably, and Safely Reduces LDLc in Non-Human Primates at Therapeutically Relevant Doses

Duncan-lewis Christopher, Narsineni Lokesh, Karmarkar Maitreyee, Li Yuexuan, Krupa Oleh, Bucher Simon, Sharma Neel, Chang Han, Schulwach Keith, Ripley-phipps Sterling, Tran Vanessa, Fernandes Jason, Goh Natalie, Deiter Fred, Reimer Kirsten, Mrak Anna, Eggers Michelle, Sze Christie, Mirotsou Maria, Oresic Bender Kristina, Bardai Farah, Denny Sarah, Charles Emeric, Khakoo Aarif, Oakes Benjamin, Keller Steven, Alcantara-lee Raniel, Santamaria Carlos, Bale Shyam Sundhar, Kozy Heather, Corbo Lana

Additive Value of Lipoprotein(a), Remnant Cholesterol, and Inflammation for Risk Stratification of Myocardial Infarction: Evidence from the UK Biobank

Kazibwe Richard, Schaich Christopher, Kingsley Jeffrey, Rikhi Rishi, Namutebi Juliana, Chevli Parag, Mirzai Saeid, Shapiro Michael

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available